1. |
|
|
2. |
|
|
3. |
|
|
4. |
|
|
5. |
- Rodriguez-Rodriguez, P, et al.
(författare)
-
Corrigendum
- 2018
-
Ingår i: Brain : a journal of neurology. - : Oxford University Press (OUP). - 1460-2156. ; 141:5, s. e43-
-
Tidskriftsartikel (refereegranskat)
|
|
6. |
|
|
7. |
- Oeckl, P., et al.
(författare)
-
Blood beta-synuclein is related to amyloid PET positivity in memory clinic patients
- 2023
-
Ingår i: Alzheimers & Dementia. - 1552-5260. ; 19:11, s. 4896-4907
-
Tidskriftsartikel (refereegranskat)abstract
- Introduction: beta-synuclein is an emerging blood biomarker to study synaptic degeneration in Alzheimert's disease (AD), but its relation to amyloid-beta (A beta) pathology is unclear. Methods: We investigated the association of plasma beta-synuclein levels with ([18F])flutemetamol positron emission tomography (PET) in patients with AD dementia (n = 51), mild cognitive impairment (MCI-A beta+ n = 18, MCI-A beta-n = 30), non-AD dementias (n = 22), and non-demented controls (n = 5). Results: Plasma beta-synuclein levels were higher in A beta+(AD dementia, MCI-A beta+) than in A beta-subjects (non-AD dementias, MCI-A beta-) with good discrimination of A beta+ from A beta-subjects and prediction of A beta status in MCI individuals. A positive correlation between plasma beta-synuclein and A beta PET was observed in multiple cortical regions across all lobes. Discussion: Plasma beta-synuclein demonstrated discriminative properties for A beta PET positive and negative subjects. Our data underline that beta-synuclein is not a direct marker of A beta pathology and suggest different longitudinal dynamics of synaptic degeneration versus amyloid deposition across the AD continuum.
|
|
8. |
|
|
9. |
- Parrado-Fernandez, C, et al.
(författare)
-
Corrigendum
- 2019
-
Ingår i: Journal of cellular and molecular medicine. - : Wiley. - 1582-4934 .- 1582-1838. ; 23:6, s. 4489-4489
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|
10. |
|
|